Wednesday, February 08, 2017 2:25:36 AM
Anyway for the mighty Merck to sell just $14m of Sivextro in 2016 is pretty amazing. It just shows how much Cubist overpaid for Trius. So we were extremely lucky to get what we got! I have owned 4 biotech shares that sold out for cash plus CVRs. It looks like I'm going to get nothing from any of the CVRs. My view is that I'm a very lucky guy - the shares of all 4 were worth considerably less than the cash that I got.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM